Avoro Capital Advisors LLC — MADRIGAL PHARMACEUTICALS INC MDGL: Quarterly 13F Position History
Avoro Capital Advisors LLC has reported MADRIGAL PHARMACEUTICALS INC (MDGL) on 32 13F-HR filings in Pactolio's tracked window, first appearing in Q2 2018. As of Q1 2026, the position is sized at 1,818,181 shares ($951.8M market value, 9.38% of the equity book). Quarter-over-quarter share count change: + 10,681 (+0.6%) .
- 1,818,181Shares Held (Latest Filing)
- $951.8MReported Market Value (Latest Filing)
- 9.38%Portfolio Weight (% of 13F Equity Book)
- +10,681Quarter-over-Quarter Share Change
- -$100.8MQuarter-over-Quarter Value Change
- 2,055,555Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 32 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 1,818,181 | +10,681 | +0.6% | $951.8M | 9.38% | $523.47 |
| Q4 2025 | 1,807,500 | 25,500 | -1.4% | $1.05B | 10.35% | $582.34 |
| Q3 2025 | 1,833,000 | 42,000 | -2.2% | $840.7M | 10.88% | $458.66 |
| Q2 2025 | 1,875,000 | 147,222 | -7.3% | $567.5M | 9.94% | $302.64 |
| Q1 2025 | 2,022,222 | 6,778 | -0.3% | $669.8M | 10.46% | $331.23 |
| Q4 2024 | 2,029,000 | 0 | — | $626.1M | 8.86% | $308.57 |
| Q3 2024 | 2,029,000 | 26,555 | -1.3% | $430.6M | 6.28% | $212.22 |
| Q2 2024 | 2,055,555 | +111,111 | +5.7% | $575.9M | 7.67% | $280.16 |
| Q1 2024 | 1,944,444 | +55,556 | +2.9% | $519.2M | 6.06% | $267.04 |
| Q4 2023 | 1,888,888 | +333,888 | +21.5% | $437.1M | 6.04% | $231.38 |
| Q3 2023 | 1,555,000 | +39,849 | +2.6% | $227.1M | 3.54% | $146.04 |
| Q2 2023 | 1,515,151 | 151,515 | -9.1% | $350.0M | 4.75% | $231.00 |
| Q1 2023 | 1,666,666 | +6,666 | +0.4% | $403.8M | 5.99% | $242.26 |
| Q4 2022 | 1,660,000 | +125,000 | +8.1% | $481.8M | 7.20% | $290.25 |
| Q3 2022 | 1,535,000 | 0 | — | $99.8M | 1.84% | $64.99 |
| Q2 2022 | 1,535,000 | +110,000 | +7.7% | $109.9M | 2.17% | $71.58 |
| Q1 2022 | 1,425,000 | 0 | — | $139.8M | 2.55% | $98.12 |
| Q4 2021 | 1,425,000 | 0 | — | $120.8M | 2.06% | $84.74 |
| Q3 2021 | 1,425,000 | 0 | — | $113.7M | 1.79% | $79.79 |
| Q2 2021 | 1,425,000 | 0 | — | $138.8M | 2.42% | $97.41 |
| Q1 2021 | 1,425,000 | +200,000 | +16.3% | $166.7M | 2.88% | $116.97 |
| Q4 2020 | 1,225,000 | +335,000 | +37.6% | $136.2M | 2.35% | $111.17 |
| Q3 2020 | 890,000 | +540,000 | +154.3% | $105.7M | 1.50% | $118.73 |
| Q2 2020 | 350,000 | +1,000 | +0.3% | $39.6M | 0.78% | $113.25 |
| Q1 2020 | 349,000 | 0 | — | $23.3M | 0.79% | $66.76 |
| Q4 2019 | 349,000 | 11,000 | -3.1% | $31.8M | 0.94% | $91.11 |
| Q3 2019 | 360,000 | 0 | — | $31.0M | 1.29% | $86.22 |
| Q2 2019 | 360,000 | +50,000 | +16.1% | $37.7M | 1.31% | $104.81 |
| Q1 2019 | 310,000 | +85,000 | +37.8% | $38.8M | 1.68% | $125.26 |
| Q4 2018 | 225,000 | 238,000 | -51.4% | $25.4M | 1.52% | $112.72 |
| Q3 2018 | 463,000 | 26,536 | -5.4% | $99.1M | 4.56% | $214.13 |
| Q2 2018 | 489,536 | — | — | $136.9M | 5.28% | $279.69 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Avoro Capital Advisors LLC first disclose a MDGL position in 13F-HR filings?
Avoro Capital Advisors LLC first reported MADRIGAL PHARMACEUTICALS INC (MDGL) on its 13F-HR filing for the period ending 2018-06-30 (Q2 2018). The position has appeared on 32 reported quarters within Pactolio's tracked window.
What was Avoro Capital Advisors LLC's most recent quarter-over-quarter share-count change in MDGL?
Between Q4 2025 and Q1 2026, Avoro Capital Advisors LLC added 10,681 shares of MDGL (+0.6%), bringing the total reported position to 1,818,181 shares at a market value of $951.8M.
Does the implied price-per-share represent Avoro Capital Advisors LLC's cost basis in MDGL?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.